Enanta Pharmaceuticals Announces New Preclinical Data for its Respiratory Virology Programs to be Presented at the 12th International RSV Symposium
Oral Presentation
Date:
Time: 9:45 –
Title: “EDP-323, a Novel L-Protein Inhibitor, for the Treatment of Respiratory Syncytial Virus”
Presenter:
Poster Presentations
Date:
Time: 6:00 –
Title: “In
Presenter:
Date:
Time: 6:00 –
Title: “An Improved Toolkit for In Vitro hMPV Characterization”
Presenter:
Date:
Time: 6:00 –
Title: “Evaluation of a Human 3D Airway Tissue Culture Model for the Study of Respiratory Syncytial Virus Infection and the Development of Antiviral Drugs”
Presenter:
Posters will be available to view on the conference platform during the conference. Further information about the 12th International RSV Symposium can be found here.
About
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development programs include clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).
Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005202/en/
Media and Investors
617-744-3848
jviera@enanta.com
Source: